Compare IMUX & ALIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMUX | ALIS |
|---|---|---|
| Founded | 2016 | 2024 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 83.9M |
| IPO Year | 2013 | N/A |
| Metric | IMUX | ALIS |
|---|---|---|
| Price | $1.18 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 58.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $9.87 |
| 52 Week High | $1.35 | $10.07 |
| Indicator | IMUX | ALIS |
|---|---|---|
| Relative Strength Index (RSI) | 76.19 | 48.93 |
| Support Level | $0.61 | $9.87 |
| Resistance Level | N/A | $10.02 |
| Average True Range (ATR) | 0.12 | 0.01 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 95.79 | 0.14 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.